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CpxRA is a two-component signal transduction system (2CSTS) found in many drug-resistant Gram-negative bacteria. In re-
sponse to periplasmic stress, CpxA autophosphorylates and donates a phosphoryl group to its cognate response regulator, CpxR.
Phosphorylated CpxR (CpxR-P) upregulates genes involved in membrane repair and downregulates multiple genes that encode
virulence factors, which are trafficked across the cell membrane. Mutants that constitutively activate CpxRA in Salmonella en-
terica serovar Typhimurium andHaemophilus ducreyi are avirulent in mice and humans, respectively. Thus, the activation of
CpxRA has high potential as a novel antimicrobial/antivirulence strategy. Using a series of Escherichia coli strains containing a
CpxR-P-responsive lacZ reporter and deletions in genes encoding CpxRA system components, we developed and validated a
novel cell-based high-throughput screen (HTS) for CpxRA activators. A screen of 36,000 compounds yielded one hit compound
that increased reporter activity in wild-type cells. This is the first report of a compound that activates, rather than inhibits, a
2CSTS. The activity profile of the compound against CpxRA pathwaymutants in the presence of glucose suggested that the com-
pound inhibits CpxA phosphatase activity. We confirmed that the compound induced the accumulation of CpxR-P in treated
cells. Although the hit compound contained a nitro group, a derivative lacking this group retained activity in serum and had
lower cytotoxicity than that of the initial hit. This HTS is amenable for the screening of larger libraries to find compounds that
activate CpxRA by other mechanisms, and it could be adapted to find activators of other two-component systems.
The increasing prevalence of multidrug-resistant Gram-nega-tive bacteria has prompted urgent calls for new antibiotics (1).
Escherichia coli sequence type 131, a clonal group that expresses
extended-spectrum -lactamases (ESBLs) and quinolone resis-
tance, has emerged as a major cause of community- and health
care-associated urinary tract infections in the United States (2–4).
The Klebsiella pneumoniae carbapenemase (KPC) has rendered
some strains of K. pneumoniae resistant to all -lactams, while the
New Delhi metallo- (NDM-1) -lactamase-containing plasmid
has rendered some strains of E. coli and K. pneumoniae panresis-
tant (5–9). These developments raise the specter that several com-
mon infections, such as urinary tract infections due to E. coli or K.
pneumoniae, may soon be caused by organisms that are virtually
untreatable (5, 8, 9).
The traditional approach to discover antibiotics has been to
screen libraries of natural or synthetic products for bacterial kill-
ing activity in culture. Unfortunately, this strategy has yielded no
new targets or classes of drugs for Gram-negative bacteria over the
past 50 years (10–12). More contemporary approaches are aimed
at identifying inhibitors of novel targets essential for growth or
virulence. Attractive targets include bacterial two-component sig-
nal transduction systems (2CSTS), which typically consist of a
sensor kinase (SK) and a response regulator (RR), have no mam-
malian homologs, and involve the phosphorylation of amino ac-
ids that differ from the targets of mammalian phosphatases and
kinases. Although several inhibitors of 2CSTS have antibacterial
activity in vitro (13–16), none have achieved clinical utility in hu-
mans. The failure to develop inhibitors may be due to the redun-
dancy of 2CSTS or to the poor selectivity and bioavailability of
these compounds, which target the hydrophobic active site of the
SK (15, 16). Another approach has been to find nontraditional
therapeutics that target 2CSTS and do not cause cell death but
downregulate the expression of virulence factors (13, 16, 17). For
example, inhibition of the 2CSTS QseBC by the small molecule
LED209 increased survival in animals infected with Salmonella
enterica serovar Typhimurium or Francisella tularensis (18, 19).
Thus, there is a rationale to expand the repertoire of nontradi-
tional therapeutics that target 2CSTS.
CpxRA is a 2CSTS that allows Gram-negative bacteria to sense
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and respond to envelope stress (20–23). CpxA is an SK that spans
the cytoplasmic membrane, and CpxR is its cognate RR. Upon
sensing membrane stress, CpxA autophosphorylates on a con-
served histidine residue and subsequently donates a phosphate
group to a conserved aspartic acid residue on CpxR (20) (Fig. 1).
In E. coli, to alleviate membrane stress, phosphorylated CpxR
(CpxR-P) regulates the transcription of approximately 100 genes;
genes that maintain envelope integrity are upregulated, whereas
genes that encode secreted factors are downregulated (24–26). In
E. coli, CpxA activity is regulated by two upstream components,
CpxP and NlpE (27) (Fig. 1). The periplasmic chaperone CpxP
inhibits CpxA kinase activity. Misfolded proteins bind to CpxP
and cause it to dissociate from CpxA, activating the system. By
some unknown mechanism, surface adhesion induces the lipo-
protein NlpE to activate CpxA.
In addition to being an SK, CpxA also has phosphatase activity
for CpxR-P (20). In the absence of envelope stress, CpxA acts as a
net phosphatase, and CpxR remains inactive. When wild-type
cells are grown in minimal medium containing excess carbon,
such as 0.4% glucose, CpxR is activated by accepting phosphoryl
groups from small-molecule donors, such as acetylphosphate
(AcP) (28) (Fig. 1). Glucose-induced activation requires the lysine
acetyltransferase YfiQ (also known as Pka and PatZ) and the acet-
ylation of lysine 298 of the RNA polymerase -subunit but does
not require CpxA (28–30). A cpxA deletion mutant (cpxA) re-
sponds more robustly to glucose than does its wild-type parent,
because the cpxA mutant lacks phosphatase activity and accu-
mulates CpxR-P (28, 30). cpxA* alleles, which carry mutations in
the region encoding the sensing domain, result in constitutive
phosphorylation of CpxR; such mutants accumulate even higher
levels of CpxR-P than do cpxA mutants (21, 28).
CpxRA is found in many drug-resistant bacteria, including
Haemophilus ducreyi, Neisseria gonorrhoeae, E. coli, and K. pneu-
moniae, and is highly conserved across the Enterobacteriaceae (21,
31). In several of these pathogens, activation of CpxR by the dele-
tion of cpxA or by cpxA* mutations reduces the expression of
virulence determinants, consistent with the fact that a major func-
tion of the system is to reduce protein flow to the periplasm. AnH.
ducreyi cpxA mutant reduces the expression of seven virulence
determinants that are required for human infection (32–34).
When inoculated into the skin of human volunteers, the H. du-
creyi cpxA mutant is avirulent (32). In contrast, an H. ducreyi
cpxR mutant, which maintains wild-type levels of virulence de-
terminant expression, is fully virulent in humans (33, 35). Simi-
larly, constitutive activation of CpxRA abolishes S. enterica sero-
var Typhimurium virulence in mice (36). Mice fed a lethal dose of
the wild type and cpxR mutant become infected, while those fed
similar doses of the cpxA and cpxA* mutants do not (36). Fur-
thermore,cpxAmutants of uropathogenic E. coli (UPEC) andN.
gonorrhoeae are outcompeted by the wild type by three orders of
magnitude in their respective murine infection models (A. Jerse
and S. Spinola, unpublished data, and H. Mobley and S. Spinola,
unpublished data). Taken together, these data led us to hypothe-
size that activating CpxRA may be a broadly applicable antiviru-
lence strategy and that compounds that pharmacologically acti-
vate CpxRA will downregulate virulence determinants and allow
the host immune response to clear the infection.
To begin testing this hypothesis, we developed a high-through-
put screen (HTS) to detect compounds that activate CpxRA using
an E. coli strain containing a CpxR-responsive lacZ reporter (27).
To identify the components required for compound-induced
activation, we used an isogenic set of cpxRA mutants. Finally,
we present validation of the screen and the strategy used to
characterize the targets of hit compounds. The screen should
be amenable for the discovery of compound leads with the
potential to cripple the virulence of multidrug-resistant Gram-
negative pathogens.
MATERIALS AND METHODS
Bacterial and mammalian cell growth conditions. The bacterial strains
used in this study are listed in Table 1. The transcriptional fusion reporter
strains (27, 29, 37) and the anti-maltose binding protein (MBP)-CpxR
antibody (38) were generous gifts from Thomas Silhavy (Princeton Uni-
versity, Princeton, NJ, USA). Bacteria were grown at 37°C in TB7, a me-
dium containing 1% (wt/vol) tryptone and buffered to pH 7.0 with po-
tassium phosphate (100 mM). HepG2 hepatocellular carcinoma cells
were a generous gift from Andy Yu (Indiana University, Indianapolis, IN,
USA) and were grown in RPMI 1600 medium (Gibco) containing 10%
fetal calf serum (Sigma) and 1 mM sodium pyruvate (Sigma) at 37°C with
5% CO2.
FIG 1 CpxRA two-component signal transduction system (27). In response to membrane stress, CpxP dissociates from CpxA. CpxA phosphorylates on a
conserved histidine residue and donates a phosphate group to a conserved aspartic acid residue on CpxR (pathway 1, left). A PcpxP-lacZ transcriptional fusion
serves as a reporter for CpxR activity. In response to glucose, CpxR can accept phosphoryl groups from acetyl phosphate (AcP), and transcription requires the
acetylation of RNA polymerase (RNAP) and YfiQ (pathway 2, right) (29). Compounds that activate CpxRA might target CpxP, NlpE, CpxA, CpxR, or YfiQ (29).
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-galactosidase assay. The E. coli PcpxP=-lacZ reporter strains were
cultured overnight at 37°C in TB7 supplemented with 0.4% glucose. The
following day, the cultures were diluted to an optical density at 600 nm
(OD600) of 0.1 in 1.7 TB7 with glucose, and 30 l of the diluted culture
were distributed to wells of a 384-well plate containing 20 l of vehicle or
compound and grown at 37°C without shaking. After 5 h, 50 l of All-in-
One -galactosidase reagent (Pierce), which was diluted 2.5-fold with
TB7 medium, was added. The OD420, OD550, and OD600 of the wells were
measured using a Molecular Devices SpectraMax 384 spectrophotometer,
and the Miller units (MU) were calculated as described previously (39).
When appropriate, 10% (vol/vol) human AB serum (HyClone) was sup-
plemented. The effect of 10% serum on the activity of the compound was
analyzed using a mixed-effects analysis of variance (ANOVA) model.
Z=-factor calculation. Each 384-well plate was loaded with the wild
type, cpxA, or cpxA* (PAD455) strain in 22 columns, and medium con-
trols were placed in the remaining 2 columns. The growth conditions were
as described for the -galactosidase assays. The Z= factor is defined as 1
[(3 SD of sample 3 SD of control)/(mean of samplemean of control)]
(SD, standard deviation) and was calculated as described previously (40)
from the results from two independent experiments.
Compound collection. We screened 36,000 compounds of a library
containing approximately 225,000 compounds obtained from the Chem-
Bridge and ChemDiv collections, housed at the Indiana University Chem-
ical Genomics Core Facility. The library contains nonredundant drug-like
small-molecule compounds and provides significant diversity with a mul-
tidimensional chemical space. The compounds in the library obey Lipin-
ski’s rules for good solubility, absorption, distribution, metabolism, and
excretion profiles (41). Commercially available hit compounds, including
compound 1, and analogs, including compounds 1a and 1b, were pur-
chased from ChemBridge Hit2Lead, TimTec, or ChemDiv and dissolved
in dimethyl sulfoxide (DMSO).
High-throughput screen. A Tecan Freedom EVO robotic liquid han-
dling device was used to transfer 20l of 15g/ml compound solutions in
single wells of columns 1 to 22 of a 384-well plate. The wells in columns 23
and 24 received sterile vehicle. Wild-type bacteria were delivered to all
other wells, except for the controls, which contained medium only or the
untreatedcpxAmutant. The growth conditions were as described for the
-galactosidase assays. The final concentration of each compound was 6
g/ml (approximately 15M), and the final concentration of DMSO was
0.5%. Compounds were defined as hits if their treatment met two criteria:
(i) it must increase the-galactosidase activity (in Miller units) of the wild
type more than the mean plus three standard deviations of the activity of
the untreated wild-type wells, and (ii) it must not decrease growth (in
optical density at 600 nm) more than the mean minus three standard
deviations of the untreated cpxA mutant on the plate. During rescreen-
ing of hit compounds and the testing of new compounds, the Miller units
were determined at the beginning of the assay and before and after treat-
ment with the -galactosidase reagent to exclude compounds that are
intrinsically yellow in color.
Bacterial viability assays. To determine the compound effect on bac-
terial viability, cultures were treated with vehicle or compound, and the
CFU per milliliter were determined at 0 and 5 h. For the CFU counts, 10l
of multiple serial dilutions were plated on LB agar and grown at 37°C
overnight. Ciprofloxacin (2.5 M) was used as a control for cell death.
CpxRApathwaymutant assay.The-galactosidase activity (in Miller
units) of the wild-type and cpxRA pathway mutant reporter strains was
measured in the presence or absence of 0.4% glucose and in the presence
of DMSO or 80 M compound dissolved in DMSO. The fold change was
determined by dividing the Miller units obtained in the presence of com-
pound by the Miller units in DMSO only. The fold change data were
analyzed using a mixed-model ANOVA with experiment as a random
effect to account for within-experiment correlations; they were adjusted
for multiple comparisons using Dunnett’s procedure.
Detection of phosphorylated CpxR. Wild-type and cpxA bacteria
were grown overnight in side-arm flasks in TB7 broth without glucose and
diluted to an OD600 of about 0.1 in 1.7 TB7 supplemented with glucose.
To each well of a 384-well plate, 30 l of this dilution was added to 20 l
of compound 1 (80M) dissolved in DMSO or of DMSO alone (192 wells
for each strain/treatment). After 5 h of incubation at 37°C, the wells were
pooled and harvested by centrifugation. All processing was carried out at
4°C. The cells were washed once in phosphate-buffered saline (pH 7.4)
and suspended in 2 Laemmli lysis buffer, according to the bacterial
pellet weight. As controls, 10 M His6-CpxR, expressed and purified as
previously described (30), was incubated with 0 or 20 mM AcP at 30°C for
15 min (30). Twenty-microliter and 5-l aliquots of each cell lysate and
AcP treatment, respectively, were separated on a Phos-tag gel, which was
prepared according to the procedure described by Lima and colleagues
(30) and the manufacturer’s protocol, with some modifications. Phos-tag
acrylamide was purchased from Wako. The stacking gel contained 4%
acrylamide/bis-acrylamide prepared in 350 mM bis-Tris (pH 6.8). The
separating gel contained 10% acrylamide/bis-acrylamide, 25 M Phos-
tag acrylamide, and 50 M Zn(NO3) prepared in 350 mM bis-Tris (pH
6.8), and was degassed with stirring for 2 min prior to pouring. The gel was
run at 4°C in morpholinepropanesulfonic acid (MOPS) buffer (0.1 M
MOPS, 0.1 M Tris, 5 mM sodium bisulfite, and 0.1% SDS) for 2 to 3 h at
40 milliamps, and the buffer was refreshed each hour. The gel was washed
for 15 min in Towbin transfer buffer containing 1 mM EDTA and then for
30 min in standard Towbin transfer buffer. The proteins were transferred
to a polyvinylidene difluoride membrane using a wet transfer method.
Tris-buffered saline containing 0.1% Tween 20 (TBST) was used for
washing, and TBST supplemented with 5% skim milk was used for block-
ing and antibody incubations. The membrane was blocked for 1 h and
probed overnight at 4°C with 1:10,000 anti-MBP-CpxR antibody. The
secondary antibody goat anti-rabbit IgG-horseradish peroxidase conju-
gate was used at a 1:5,000 dilution for 1 h at room temperature. Densi-
tometry values were determined using Photoshop, and the ratio of
CpxR-P to CpxR was analyzed by a one-tailed paired Student’s t test.
Cytotoxicity assay. To measure cytotoxicity, 20,000 HepG2 (50l for
the 5-h assay and 100 l for the 24-h assay) cells were plated per well of
tissue culture-treated 96-well plates and allowed to adhere for 3 h. The
cells were treated with an equal volume of medium containing either 1%
DMSO (vehicle control) or 2 compound, such that the final concentra-
tion of DMSO was 0.5%. After 5 and 24 h, lactate dehydrogenase (LDH)
release was measured using the CytoTox 96 nonradioactive cytotoxicity
assay (Promega), according to the manufacturer’s instructions. We deter-
mined the percent cell death by adjusting the vehicle-treated and Triton
X-100-treated cells to 0 and 100% death, respectively. The 50% inhibitory
concentration (IC50) after 24 h of incubation was determined using the
GraphPad Prism 6.0 software. The relative cytotoxicities of compounds 1
and 1a were analyzed using a mixed-effects ANOVA model.
TABLE 1 E. coli strains used in this study
Strain Description Reference or source
PAD282 MC4100 [F araD139 (argF-
lac)U169 rpsL150 (Strr) relA1
flhD5301 deoC1 ptsF25 rbsR]
	RS88 (cpxP=-lacZ)a
27
PAD292 PAD282 cpxR1::spc (spectinomycin
insertion in cpxR with polar
effect on cpxA)
27
PAD348 PAD282 cpxA::cam DiGiuseppe and Silhavy
(Princeton University)
PAD455 PAD282 cpxA24 zii::Tn10 37
PAD485 PAD282 nlpE::spc 27
PAD488 PAD282 cpxP::kan 27
AJW3142 PAD282 yfiQ::kan 29
TR48 PAD282 cpxA101 lamBA23D
zjb::Tn10Kn
20
a Strr, streptomycin resistant.
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RESULTS
Development andvalidationof aHTSassay forCpxRactivators.
In E. coli, cpxP is the promoter most highly upregulated by phos-
phorylated CpxR (25). To detect CpxR activation, we used an
isogenic set of E. coli reporter strains that contain a chromosomal
cpxP promoter-lacZ fusion (27) (Fig. 1). We developed a 384-well
plate assay to detect compounds that activate the reporter in the
wild type, using either the cpxA or the cpxA* mutants as stan-
dards for cpxP transcription and growth. The assay was performed
in TB7 broth containing 0.4% glucose, which fosters the forma-
tion of AcP. We reasoned that this growth condition would allow
the detection of compounds that activate CpxR by augmenting
CpxA kinase activity or inhibiting CpxA phosphatase activity.
After 5 h of growth in the glucose-enriched medium, the -ga-
lactosidase activity of the cpxA and cpxA* mutants was approx-
imately 10- and 20-fold greater, respectively, than that of their
wild-type parent (Fig. 2A and B). The quality of our assay was
assessed by calculating the Z= factor using the Miller units of the
wild-type and thecpxA and cpxA* mutants (Fig. 2A and B). A Z=
factor of0.5 is suitable for HTS (40); our calculated Z= factor was
0.5 for the cpxA mutant and 0.55 for the cpxA* mutant, indicat-
ing that the assay distinguished between baseline and enhanced
CpxRA activity. As expected, the cpxR mutant exhibited less
-galactosidase activity than that of its wild-type parent (data not
shown). On the basis of these data, the first criterion for a com-
pound to be considered a hit was that it must increase -galacto-
sidase activity (in Miller units) of the wild type more than the
mean plus three times the standard deviation of the activity of the
untreated wild type.
In interpreting the results of the HTS, we considered the fact
that antibiotics indirectly activate CpxRA (42, 43). For example,
gentamicin induces protein mistranslation and fosters the trans-
location of misfolded proteins to the periplasm, activating the
system (44). To exclude indirect activators, such as antibiotics, we
established growth parameters for the screen. After 5 h, the aver-
age optical density at 600 nm of the wild type and the cpxA and
cpxA* mutants was 0.5 
 0.03 (mean 
 standard deviation),
0.24 
 0.01, and 0.21 
 0.01, respectively (Fig. 2C and D). The
growth impairment in the activating mutants suggested that com-
pounds that activate CpxR in the wild type would likely reduce
growth to the extent seen in the cpxA or cpxA* mutants. Thus, a
second criterion for a compound to be considered a hit is that it
may not inhibit the growth of the wild type more than the mean
minus three times the standard deviation of the growth of the
cpxA* mutant.
We performed a mock screen in which the wild type was inoc-
ulated in 372 wells of the plate, and thecpxA and cpxA* mutants
were inoculated in 5 wells each. After 5 h of growth, the reporter
activity of the mutants was clearly distinguishable from that of the
wild type (Fig. 3). Thus, compounds that activate CpxRA in the
wild type should be distinguishable from background.
Whole-cell screen forCpxRAactivators.A 36,000-compound
small-molecule library was screened at approximately 15 M for
the induction of -galactosidase activity in the wild-type reporter
strain; each compound was tested in a single well. This screen
resulted in 340 putative hits. Of 324 compounds available for re-
screening, 10 activated the reporter and did not inhibit growth by
optical density at 600 nm criterion (Table 2) and satisfied both hit
criteria. As controls, we included the bactericidal antibiotic cipro-
floxacin and the bacteriostatic antibiotic spectinomycin; both
antibiotics activated the reporter in the wild type and caused com-
plete growth inhibition (Table 2). The 10 hit compounds be-
FIG 2 Development of screening assay for CpxA activators. (A and B) -Galactosidase activity of 352 wells containing the wild type was plotted with 384 wells
each of thecpxA (A) and cpxA* (B) mutants. The graphs are representative of the results from 2 independent experiments; average Z= factors were 0.5 and 0.55
for cpxA and cpxA*, respectively. (C and D) Corresponding growth (optical density at 600 nm) of the wild type was plotted with the cpxA (C) and cpxA* (D)
mutants. The graphs are representative of the results from 2 independent experiments. Œ, untreated wild type; , cpxA mutant; , cpxA* mutant; solid
horizontal lines, mean values of the Miller units (A and B) and OD600 (C and D) for each strain; dashed lines, 3 standard deviations from the mean.
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longed to three structural groups: six nitroaniline/nitroindole
derivatives, three quinolone derivatives, and one furoxan-pyrida-
zine compound that has vasorelaxant activity (45).
We tested the 10 initial hits and 88 commercially available an-
alogs, including 80 nitroanilines/nitroindoles, 17 quinolones, and
the furoxan-pyridazine compound. We performed dose-response
studies from 1 nM to 100 M. Most compounds reproducibly
activated the reporter in the wild type in concentrations ranging
from 10 to 100 M (data not shown). Importantly, no com-
pounds increased reporter activity in the cpxR mutant (data not
shown and Fig. 4A), validating the specificity of the screening
assay.
The three most potent compounds in terms of cpxP transcrip-
tion that also passed the growth inhibition criterion included two
nitroindoles and one quinolone. At concentrations ranging from
5 to 80M compound, we measured the viable CFU of the treated
wild type and that of the untreated wild type and the cpxA and
cpxR mutants. By quantitative culture, after 5 h, the untreated
wild type increased CFU counts by 42-fold, the cpxR mutant by
20-fold, and the cpxA mutant by 13-fold (data not shown). In
contrast, the CFU of the ciprofloxacin-treated wild type decreased
almost 105-fold (data not shown). At their optimal activating con-
centrations, the candidate quinolone and one candidate nitroin-
dole caused a 102-fold reduction in viable CFU (data not shown),
suggesting that they activated the system by killing the bacteria
and were not valid candidates. However, in the presence of 40M
the other candidate nitroindole (6-nitro-2,3,4,9-tetrahydro-1H-
carbazol-1-amine; catalog no. 5302860; ChemBridge), here re-
ferred to as “compound 1,” the wild-type CFU increased 4.5-fold
(data not shown), suggesting that compound 1 was not activating
the system through an antibiotic effect.
Characterization of compound 1. Since compound 1 acti-
vated cpxP transcription and permitted bacterial growth, we per-
formed dose-response assays in the wild type and cpxR mutant;
the untreated cpxA mutant was included for comparison. A
dose-dependent increase in reporter activity was observed in wild-
type bacteria but not in the cpxR mutant (Fig. 4A). In the pres-
ence of the highest concentrations of the compound, reporter ac-
tivity in the wild type was induced to levels higher than those
observed in the untreated cpxA mutant (Fig. 4A, dashed lines).
In contrast, the antibiotic ciprofloxacin induced reporter activ-
ity similar to the lower level of activity observed in the cpxA
mutant. No additional reporter activity was observed at con-
centrations of 5 M ciprofloxacin, likely due to its bacteri-
cidal activity (Fig. 4B).
Wild-type bacteria treated with compound 1 mimicked the
-galactosidase activity and growth observed with thecpxA mu-
tant; thus, we hypothesized that the compound inhibited CpxA
phosphatase activity. If this were true, compound 1 should acti-
vate the reporter only in the presence of glucose, CpxA, CpxR, and
YfiQ (29). Therefore, we treated the wild-type strain and its iso-
geniccpxA,cpxR, andyfiQ mutants grown in the presence or
absence of glucose with 80 M compound 1. We calculated the
fold change in reporter activity in compound-treated versus un-
treated wells. Compound 1 maximally activated the reporter in
the presence of glucose in the wild type (P  0.001) (Fig. 5A); it
was not active in the cpxA (P  0.0001), cpxR, or yfiQ mu-
tants, suggesting that compound 1 likely targeted CpxA. To inves-
tigate potential upstream targets, 80 M compound 1 was tested
with the nlpE and cpxP reporter strains (27). The fold change
increase in -galactosidase activity in the nlpE and cpxP mu-
tants was not significantly different than the activity in their wild-
type parent (data not shown). Taken together, the data suggest
that compound 1 either generates a CpxA-activating signal or in-
hibits CpxA phosphatase activity.
To test the hypothesis that compound 1 inhibits CpxA phos-
phatase activity, we used the cpxA* allele cpxA101 (20). In vitro
FIG 3 Validation of HTS assay. -Galactosidase activity of 372 wells of the
wild type (Œ) and 5 wells each of the cpxA* () and cpxA () mutants.
FIG 4 Compound 1 activates CpxRA. Shown are the dose responses of compound 1 (A) and ciprofloxacin (B) with wild-type (WT) andcpxR reporter strains.
The reporter activity was determined after 5 h of incubation with increasing concentrations of compound 1 or ciprofloxacin. Data are means 
 standard
deviations from three independent experiments. The dashed lines represent the mean plus and minus three standard deviations of the untreatedcpxA mutant.
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TABLE 2 Structure, compound-induced activity (Miller units), and growth (OD600) of compound-treated cells relative to wild type in the
confirmatory assay
Hit no. Structural groupa Structure Supplier IDb
Fold change relative to
WT inc:
MU OD600
1 A CB5139225 2.12 1.03
2 CB5139230 4.00 1.00
3 CB5221072 2.13 1.13
4 CB5315987 2.26 1.10
5 CB5406089 2.31 1.03
6 CB5302860 27.64 0.69
7 B CD5076-4234 5.57 0.69
8 CD5076-2815 4.16 1.15
9 CD5081-0145 12.29 0.82
10 C CB5314731 4.89 0.77
Ciprofloxacin 9.05 0.20
Spectinomycin 10.61 0.21
a A, B, and C are the 3 classes of hits identified in the high-throughput screen: nitroaromatics, quinolones, and the furoxan-pyridazine compound, respectively.
b ID, identification; CB, ChemBridge; CD, ChemDiv.
c MU, Miller units; WT, wild type.
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phosphorelay assays showed that CpxA101 retains autokinase and
CpxR kinase activity but lacks CpxR-P phosphatase activity (20).
We treated the wild-type strain and the cpxA101 mutant in the
presence or absence of glucose with 80 M compound 1 and cal-
culated the fold change in reporter activity in compound-treated
versus untreated wells. As observed previously, the compound
maximally activated the reporter in wild-type bacteria in the pres-
ence of glucose, whereas significantly less activity was observed in
the absence of glucose (P  0.0001) (Fig. 5B). In contrast, the
compound-induced reporter activity did not differ in the presence
or absence of glucose in the cpxA101 mutant (Fig. 5B). The com-
pound-induced reporter activity of the wild type was significantly
higher than that in the cpxA101 mutant (P  0.0001) (Fig. 5B).
These results also suggested that compound 1 predominantly acts
by inhibiting CpxA phosphatase activity.
Compound 1 causes accumulation of phosphorylated CpxR.
We reasoned that if compound 1 inhibits CpxA phosphatase ac-
tivity, it should induce an increase in CpxR-P levels. Lima and
colleagues (30) recently used Phos-tag SDS-PAGE to detect
CpxR-P in E. coli grown in the presence of 0.4% glucose. To test if
compound 1 induces CpxR-P accumulation, we cultured the wild
type in the presence of 0.4% glucose and with or without 80 M
compound 1. As controls, we included recombinant CpxR that
was untreated or treated with 20 mM AcP, along with the un-
treated cpxA mutant grown in the presence of glucose. We har-
vested the cells after 5 h, prepared cell lysates, separated proteins
by Phos-tag SDS-PAGE, and detected endogenous CpxR and
CpxR-P by Western immunoblot with anti-MBP-CpxR antise-
rum. As shown in Fig. 6A, the treatment of CpxR with AcP in-
creased the fraction of CpxR-P. Treatment with compound 1 in-
duced an accumulation of CpxR-P levels in wild-type cells
equivalent to that in the activated cpxA mutant. Total CpxR
levels were higher in the cpxA mutant and treated wild type,
consistent with the fact that CpxR-P positively autoregulates its
transcription. To accurately compare the samples, the two CpxR
fractions were quantified by densitometry. Compared to the un-
treated wild type, compound 1 treatment trended toward increas-
ing the ratio of CpxR-P to CpxR in the wild type by 3-fold (P 
0.057) (Fig. 6B).
Activity of compound 1 derivatives. To determine whether
the nitro and amine moieties of compound 1 were necessary for
activity, we obtained two derivatives: compound 1a (2,3,4,9-tet-
rahydro-1H-carbazol-1-amine; catalog no. 8019-9961; Chem-
Div), which lacks the nitro group, and compound 1b (3-nitro-
5,6,7,8,9-pentahydro-4aH-carbazole; catalog no. ST024298;
TimTec), which lacks the amine group (Fig. 7A). The activity of
the three compounds was evaluated in the wild-type reporter
strain in the presence of 0.4% glucose. The activity of compound
1a was not significantly different than that of compound 1,
whereas compound 1b elicited little reporter activity (P  0.005
versus compound 1 andP 0.007 versus compound 1a) (Fig. 7B).
Thus, activation of the reporter depended on the presence of the
amine group and not the nitro group. Using the maximum re-
FIG 5 Compound 1 activity requires glucose, CpxA, CpxR, YfiQ, and CpxA phosphatase activity. The fold changes in reporter activity after treatment with 80
M compound 1 in the presence or absence of glucose in wild type (WT) and the cpxA, cpxR, and yfiQ mutants (A) or in WT and the cpxA101 mutant (B)
are shown. For each strain, the fold change was calculated by dividing the -galactosidase activity (in Miller units) of the compound-treated wells by the Miller
units of the untreated wells. The data are the average and standard deviation from three independent experiments.
FIG 6 Compound 1 induces phospho-CpxR accumulation. (A) Composite
representative Western blot of His6CpxR incubated with 0 or 20 mM AcP, and
the cpxA mutant and WT grown in medium with 0.4% glucose and 0 or 80
M compound. Note that His6CpxR migrates slower than native CpxR. (B)
The ratio of CpxR-P to CpxR was determined using densitometry; the data are
the mean and standard deviation results from 4 independent experiments.
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porter activity induced by each compound, we estimate the 50%
effective concentrations (EC50s) to be 25 and 30 M for com-
pounds 1 and 1a, respectively. By quantitative culture, wild-type
bacteria grew 5.3-fold in the presence of 40 M compound 1a.
Thus, the CpxRA activation induced by compound 1a mimics that
of compound 1.
Activity in surrogate mammalian systems. To determine the
potential utility of this class of compounds in a mammalian
model, we next assessed their activity in the presence and absence
of 10% human AB serum. Whereas the presence of serum trended
toward reducing the activity of compound 1 (P 0.058) (Fig. 8A),
the activity of compound 1a was not significantly reduced in the
presence of serum (Fig. 8B). These results suggested that com-
pound 1a could be active in vivo.
After validating the compound activity in serum, we next as-
sessed their effects on mammalian cell viability. The cytotoxicity
of compounds 1 and 1a was determined using HepG2 hepatocel-
lular carcinoma cells. HepG2 cells were treated with increasing
concentrations of compounds 1 and 1a for 5 and 24 h. Cell viabil-
ity was determined by measuring LDH release via 3-(4,5-dimeth-
yl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) re-
duction. After 5 h, compounds 1 and 1a caused10% and 5% cell
death, respectively (P 0.21). After 24 h, compound 1 had an IC50
of 63 M, whereas compound 1a was less cytotoxic, with an IC50
of 139 M (P  0.03) (Fig. 8C). Thus, the cytotoxicity of com-
pound 1 after 24 h of incubation was reduced with the removal of
the nitro group, consistent with the fact that nitro groups are often
implicated in cytotoxicity (46).
DISCUSSION
Because bacterial 2CSTS frequently have essential functions and
lack mammalian homologs, there has been considerable interest
in targeting 2CSTS for antimicrobials (13–15, 18, 47). The mode
of action of reported 2CSTS-targeted compounds is the inhibition
of SK activity or interference with the binding of the RR to its
promoter (16, 18, 48). To the best of our knowledge, this is the first
report describing a compound that activates, rather than inhibits,
a 2CSTS.
In this study, we developed and validated a novel HTS based on
genetic activation of the cpxRA system. We established growth and
reporter activity cutoffs using the untreated wild type and cpxA
and cpxA* mutants grown in the presence of glucose. As shown in
Fig. 2 and 3, reporter activity in thecpxA and cpxA* mutants was
readily distinguishable from the wild-type reporter activity, pro-
viding a robust HTS assay. The facile nature of the-galactosidase
assay makes this a broadly applicable screening strategy.
Most biochemical screens performed in our core facility have
typical hit rates of 0.1 to 0.2%. Our limited screen of 36,000 com-
pounds yielded 340 hits, 10 of which were confirmed, giving a hit
rate of 0.027%. Performing the screen in wild-type E. coli may
account for the low hit rate, due to limited uptake and/or efflux of
the small molecules. The archetype of multidrug efflux pumps in
Enterobacteriaceae is the AcrAB-TolC system; inactivation of these
transporters increases susceptibility to multiple antibacterial
agents (reviewed in references 49 and 50). By allowing more com-
pounds to reach their intracellular target, E. coli mutants lacking
AcrAB or TolC are frequently used in HTS assays to increase the
hit rate. However, the deletion of tolC activates the CpxRA system
in E. coli (51). Similarly, CpxRA is activated by the deletion of the
efflux pump genes mtrC in H. ducreyi (52) and vexAB or vexGH in
Vibrio cholerae (53). Thus, wild-type bacteria must be used to
identify CpxRA activators.
A major advantage of our cell- and reporter-based screening
assay is its ability to identify compounds that specifically activate
the CpxRA system. In theory, hit compounds might target differ-
ent members of the Cpx pathway (i.e., CpxP, NlpE, CpxA, and
CpxR), the acetyltransferase YfiQ, or enzymes involved in central
metabolism. None of the hit compounds increased reporter activ-
ity in thecpxR mutant (data not shown and Fig. 4A), confirming
the specificity of our assay. The availability of an isogenic set of
cpxRA pathway mutants bearing the reporter allowed us to infer
the likely mechanism of action of the hits. Using these mutants, we
demonstrated that compound 1 requires cpxR, cpxA, yfiQ, and
glucose for activity but does not require nlpE or cpxP (Fig. 5A).
Furthermore, the compound was not active in the cpxA101 mu-
tant, which lacks phosphatase activity (Fig. 5B). Taken together,
the data suggest that compound 1 targets CpxA and likely inhibits
its phosphatase activity.
cpxA-activating mutants in E. coli and Yersinia pseudotuber-
culosis accumulate CpxR-P (30, 54). We detected a trend for a
compound-induced increase in the phosphorylated fraction of
CpxR to levels comparable to those in the untreated cpxA mu-
tant (Fig. 6). Increased CpxR-P levels are consistent with the ob-
served increased transcription from the cpxP promoter. Although
the genetic and cell-based assays described here provide prelimi-
nary identification of targets, biochemical characterization is nec-
essary to elucidate the mode of action of the compound. In vitro
FIG 7 Activity of compound 1 and derivatives. (A) Structure of compound 1
and derivatives lacking the nitro group (1a) or the amine group (1b). (B)
Reporter activity in wild-type E. coli after 5 h of incubation with increasing
concentrations of compounds 1, 1a, and 1b. The data are the mean and stan-
dard deviation of the results from three independent experiments. The activity
of compounds 1 and 1a was not significantly different, whereas the activity of
compound 1b was reduced compared to that of compound 1 (P 0.005).
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phosphorelay assays are under way to elucidate the effect of com-
pound treatment on CpxA enzymatic activity.
The activity of a compound in the presence of serum is impor-
tant when considering potential efficacy in vivo. The presence of
10% human serum reduced compound 1 activity by approxi-
mately 50%. In contrast, compound 1a retained full activity in the
presence of serum (Fig. 8A and B). Thus, compound 1a does not
appear to nonspecifically bind to or react with proteins found in
serum. Since the compounds retained activity in serum, it was
appropriate to examine cytotoxicity. HepG2 hepatocellular carci-
noma cells were chosen as the model because the liver metabolizes
most drugs. As nitro groups are known to be cytotoxic (46), it is
not surprising that removal of the nitro group relieved the cyto-
toxicity of compound 1 2-fold (Fig. 8C and D). Thus, com-
pound 1a is an optimized first-generation derivative: it activates
CpxRA, retains complete activity in serum, and is less cytotoxic
than compound 1. In a 5-h assay, 80M compound 1a maximally
activated CpxRA and caused negligible cell death (2.2%). Thus,
medicinal optimization is under way to develop compound 1a
into a highly potent lead compound.
A consideration for the clinical utility of cpxRA activators is the
recent implication of the requirement of cpxRA activation in the
mode of action of bactericidal antibiotics. Some studies suggest
that bactericidal antibiotics kill E. coli through a “final common
death pathway,” which is mediated in part by cpxRA activation
and is inhibited by the deletion of cpxA or cpxR (42, 43, 55). How-
ever, Mahoney and Silhavy (44) showed that cpxR is not required
for killing by bactericidal antibiotics and that an E. coli cpxA*
mutant is as susceptible to ampicillin and norfloxacin as the wild
type (44). However, a cpxA* mutant is less susceptible to gentami-
cin than the wild type, perhaps because the preactivation of CpxR
by CpxA* prevents membrane damage induced by the misfolded
proteins (44). Although an E. colicpxA mutant is less susceptible
than the wild type to 5 g/ml gentamicin, the cpxA* mutant is as
susceptible as the wild type to 15 g/ml gentamicin (43), a level
that is exceeded clinically with once-daily dosing regimens. Thus,
depending on the level of activation and the antibiotic concentra-
tion, activating compounds may interfere with aminoglycosides
but not with other antibiotics.
In conclusion, we developed a robust screening strategy to
identify and characterize CpxRA activators. We plan to extend our
HTS and confirmatory screening assay to identify more potent
FIG8 Compound activity in 10% serum and cytotoxicity with HepG2 cells. (A and B) Fold change in reporter activity of wild type after treatment with increasing
concentrations of compound 1 (A) or 1a (B) in the presence or absence of 10% human AB serum. For both conditions, the fold change was calculated by dividing
the-galactosidase (-gal) activity (in Miller units) in the compound-treated wells by the Miller units of the untreated wells. The data are the mean and standard
deviation values from three independent experiments. The presence of serum trended toward reducing compound 1 activity (P 0.058), whereas the activity of
compound 1a was not significantly affected by the presence of serum. (C and D) Cytotoxicity of compounds 1 and 1a with HepG2 cells. Hepatocellular carcinoma
HepG2 cells were treated with compounds 1 and 1a for 5 h (C) and 24 h (D). Cell viability was determined by LDH release. The data are the mean and standard
deviation values from four independent experiments. The cytotoxicity caused by compound 1a was significantly less than that by compound 1 after 24 h of
incubation (P 0.03). Note the scale-adjusted ordinate axis for panels C and D.
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activators of the cpxRA system. As CpxA is highly conserved in
Enterobacteriaceae, a compound that targets CpxA would likely
have a broad spectrum of activity. Since cpxA* mutants show the
highest level of CpxR activation, compounds that enhance CpxA
kinase activity would likely be more potent than a CpxA phospha-
tase inhibitor. Compound 1a and other activators will serve as
valuable probes to further study the role of cpxRA in pathogenesis
and to address the utility of cpxRA activation as a nontraditional
antimicrobial strategy. We have named this new class of drugs
astabiotics (antimicrobial signal transduction activator-biotics).
If our approach is successful, astabiotics could be sought for dif-
ferent targets in other bacterial pathogens and potentially revolu-
tionize the field. For example, Pseudomonas aeruginosa contains a
2CSTS, AmgRS, which, although not homologous to CpxRA,
controls a similar set of genes to combat envelope stress (56).
Inhibitors of AmgRS are being studied to enhance the efficacy
of aminoglycosides; however, activators of AmgRS might have
antimicrobial effects in vivo.
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